Compare ProShares UltraPro QQQ ETF (TQQQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? ProShares UltraPro QQQ ETF trades at $81.11 (market cap $38.74B), while Vertex Pharmaceuticals Incorporated trades at $510.72 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× ProShares UltraPro QQQ ETF's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro QQQ ETF for 24 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TQQQ | VRTX | |
|---|---|---|
Market Cap | $38.74B | $127.55B |
Volume | 65,384,797 | 1,487,944 |
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $557.96 |
52-Week Low | $37.89 | $407.37 |
Typical Hold Time | 24 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $80.67, down 3.5% in the last session amid mixed technical signals. The ETF maintains a bullish overall technical rating with strong moving average support but faces neutral oscillators. Recent news highlights significant hidden costs beyond the stated 0.82% expense ratio, including financing charges that impact returns. Institutional activity shows mixed positioning with some firms reducing stakes while others add exposure.
Outlook remains volatile given TQQQ's 3x leveraged structure, which amplifies both gains and losses. The ETF faces headwinds from volatility decay and hidden costs, though AI-driven tech growth provides underlying support. Key risks include amplified drawdowns during market corrections and structural costs that erode long-term performance versus the underlying index.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
